Australia markets open in 6 hours 9 minutes

Cerevel Therapeutics Holdings, Inc. (CERE)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
40.88-0.18 (-0.44%)
At close: 04:00PM EST
40.88 0.00 (0.00%)
After hours: 04:31PM EST

Cerevel Therapeutics Holdings, Inc.

222 Jacobs Street
Suite 200
Cambridge, MA 02141
United States
844 304 2048
https://www.cerevel.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees321

Key executives

NameTitlePayExercisedYear born
Dr. N. Anthony Coles Jr., M.P.H.Executive Chairman1.14MN/A1960
Mr. Mark BodenraderVP of Finance & Chief Accounting Officer496.17kN/A1973
Dr. John J. Renger Ph.D.Chief Scientific Officer779.75k10.44M1969
Dr. Ramiro Sanchez M.D.Chief Medical Officer805.13kN/A1961
Mr. Ronald C. Renaud Jr., M.B.A.President, CEO & DirectorN/AN/A1969
Dr. Susan Altschuller M.B.A., Ph.D.Chief Financial OfficerN/AN/A1982
Mr. Matthew CalistriVice President of Investor RelationsN/AN/AN/A
Mr. Scott M. Akamine J.D.Chief Legal Officer & Corporate Secretary444.74kN/A1985
Mr. Kenneth A. DiPietroChief Human Resources OfficerN/AN/A1959
Ms. Kathleen Tregoning M.A.Chief Corporate Affairs Officer600.79kN/A1971
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures in epilepsy or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; and CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and PDE4 inhibitor for the treatment of psychiatric, neuroinflammatory, and other disorders. Cerevel Therapeutics Holdings, Inc. was founded in 2018 and is headquartered in Cambridge, Massachusetts.

Corporate governance

Cerevel Therapeutics Holdings, Inc.’s ISS governance QualityScore as of 1 February 2024 is 6. The pillar scores are Audit: 8; Board: 7; Shareholder rights: 5; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.